SCHEMBL4711448

SCHEMBL4711448

Cc1cccc(/C=C/c2cccc(Cl)c2)n1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.67
KDM4E B2RXH2 3/20 0.67
HPGD P15428 3/20 0.67
SMN1; SMN2 Q16637 2/20 0.67
CYP2C9 P11712 2/20 0.67
GRM5 P41594 2/20 0.67
CYP2D6 P10635 2/20 0.67
HIF1A Q16665 2/20 0.67
NPC1 O15118 1/20 0.67
RAB9A P51151 1/20 0.67
GRM4 Q14833 1/20 0.67
NPSR1 Q6W5P4 1/20 0.67
HDAC6 Q9UBN7 1/20 0.67
MEN1 O00255 1/20 0.67
CYP3A4 P08684 1/20 0.67
PKM P14618 1/20 0.67
TSHR P16473 1/20 0.67
NFKB1 P19838 1/20 0.67
CYP2C19 P33261 1/20 0.67
THPO P40225 1/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4711449 1.00 ALDH1A1 (0.67) ALDH1A1KDM4EHPGDSMN1; SMN2CYP2C9
SCHEMBL4713819 0.88 ALDH1A1 (0.64) ALDH1A1KDM4EHPGDSMN1; SMN2CYP2C9
SCHEMBL4713818 0.88 ALDH1A1 (0.64) ALDH1A1KDM4EHPGDSMN1; SMN2CYP2C9
SCHEMBL4711991 0.83 ALDH1A1 (0.71) ALDH1A1KDM4EHPGDSMN1; SMN2CYP2C9
SCHEMBL4712696 0.83 NPC1 (0.71) ALDH1A1KDM4EHPGDSMN1; SMN2CYP2C9
SCHEMBL4711993 0.83 ALDH1A1 (0.71) ALDH1A1KDM4EHPGDSMN1; SMN2CYP2C9
SCHEMBL4712697 0.83 NPC1 (0.71) ALDH1A1KDM4EHPGDSMN1; SMN2CYP2C9
SCHEMBL4710774 0.82 ALDH1A1 (0.60) ALDH1A1KDM4EHPGDSMN1; SMN2CYP2C9
SCHEMBL4710776 0.82 ALDH1A1 (0.60) ALDH1A1KDM4EHPGDSMN1; SMN2CYP2C9
SCHEMBL29510104 0.80 GRM4 (1.00) ALDH1A1KDM4EHPGDSMN1; SMN2CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0998459-B1 PYRIDINE DERIVATIVES NOVARTIS AG (CH) 2008-04-23 EP claimed
EP-0998459-A2 PYRIDINE DERIVATIVES Novartis AG (CH) 2000-05-10 EP claimed
WO-1999002497-A2 PYRIDINE DERIVATIVES NOVARTIS AG (CH) 1999-01-21 WO claimed
EP-0998459-B1 PYRIDINE DERIVATIVES NOVARTIS AG (CH) 2008-04-23 EP disclosed
CN-1203060-C Pyridine derivatives, compositions and uses thereof NOVARTIS AG (CH) 2005-05-25 CN disclosed
US-6656957-B1 Marked and selective modulating, especially antagonistic, action at human metabotropic glutamate receptors (mGluRs); treatment of disorders such as epilepsy, cerebral ischemias, especially acute ischemias, spasticity etc. NOVARTIS AG (CH) 2003-12-02 US disclosed
CN-1262676-A Pyridine derivatives NOVARTIS AG (CH) 2000-08-09 CN disclosed